See more : Jungfraubahn Holding AG (JFN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Quantum-Si incorporated (QSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quantum-Si incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jervois Global Limited (JRV.AX) Income Statement Analysis – Financial Results
- AgileThought, Inc. (AGILW) Income Statement Analysis – Financial Results
- Shineroad International Holdings Limited (1587.HK) Income Statement Analysis – Financial Results
- WisdomTree Energy Enhanced (BENE.L) Income Statement Analysis – Financial Results
- Bondada Engineering Limited (BONDADA.BO) Income Statement Analysis – Financial Results
Quantum-Si incorporated (QSI)
About Quantum-Si incorporated
Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 594.00K | 2.58M | 1.04M | 894.00K | 0.00 |
| Gross Profit | 488.00K | -2.58M | -1.04M | -894.00K | 0.00 |
| Gross Profit Ratio | 45.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.03M | 72.06M | 46.58M | 27.56M | 28.10M |
| General & Administrative | 42.81M | 42.29M | 46.38M | 7.98M | 7.88M |
| Selling & Marketing | 400.00K | 7.00K | 3.96M | 1.15M | 634.00K |
| SG&A | 44.63M | 42.30M | 50.33M | 9.14M | 8.52M |
| Other Expenses | 0.00 | -20.15M | -5.00M | -10.00K | 5.00K |
| Operating Expenses | 111.66M | 114.36M | 96.91M | 36.69M | 36.62M |
| Cost & Expenses | 112.25M | 114.36M | 96.91M | 36.69M | 36.62M |
| Interest Income | 0.00 | 0.00 | 2.54M | 88.00K | 823.00K |
| Interest Expense | 0.00 | 0.00 | 5.00K | 9.00K | 0.00 |
| Depreciation & Amortization | 4.16M | 2.58M | 1.04M | 894.00K | 780.00K |
| EBITDA | -91.80M | -129.86M | -95.87M | -35.80M | -35.84M |
| EBITDA Ratio | -8,484.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -111.17M | -123.84M | -96.91M | -36.69M | -36.62M |
| Operating Income Ratio | -10,274.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.21M | -8.60M | 1.92M | 78.00K | 828.00K |
| Income Before Tax | -95.96M | -132.44M | -94.99M | -36.61M | -35.79M |
| Income Before Tax Ratio | -8,868.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.60M | -6.04M | -1.00K | 5.00K |
| Net Income | -95.96M | -141.04M | -88.95M | -36.61M | -35.80M |
| Net Income Ratio | -8,868.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.68 | -1.01 | -1.12 | -6.81 | -0.26 |
| EPS Diluted | -0.68 | -1.01 | -1.12 | -6.81 | -0.26 |
| Weighted Avg Shares Out | 141.30M | 139.26M | 79.58M | 5.38M | 136.40M |
| Weighted Avg Shares Out (Dil) | 141.30M | 139.26M | 79.58M | 5.38M | 136.40M |
Assessing Quantum-Si's Path To Commercialization
Quantum-Si's proprietary protein detection platform has begun generating revenue, although it's not expected to significantly affect the cash-burn rate immediately. The company's financial stability extends till 2026 at the current burn rate, but rapid revenue generation and financial discipline are...
Quantum-Si Reports First Quarter 2023 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2023 Financial Results.
Quantum-Si Reports First Quarter 2023 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue was $254,000 on orders of $449,000 in the first quarter...
Quantum-Si Announces the Appointment of Jeff Keyes as Chief Financial Officer
GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Quantum-Si today announced the appointment of Jeff Keyes as its new Chief Financial Officer.
Quantum-Si Announces the Appointment of Jeff Keyes as Chief Financial Officer
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Jeff Keyes as its new Chief Financial Officer, effective May 15, 2023. Mr. Keyes brings more than 25 years of...
Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointments of Katherine Atkinson as Senior Vice President of Demand Generation and Corporate Brand, Alex Hutcheson as Senior Vice President of Sales...
Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments
GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Quantum-Si bolsters executive leadership team with four key appointments.
Quantum-Si to Report First Quarter 2023 Financial Results on May 11, 2023
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023. Company management will host a conference call...
Quantum-Si To Present Poster on Single-Molecule Method for Detection of Arginine Post-Translational Modifications at the AACR Annual Meeting 2023
GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it will be presenting a poster on a new method for detection of arginine post-translational modifications (PTMs) using Platinum™, the world's first...
Quantum-Si To Present Poster on Single-Molecule Method for Detection of Arginine Post-Translational Modifications at the AACR Annual Meeting 2023
GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it will be presenting a poster on a new method for detection of arginine post-translational modifications (PTMs) using Platinum™, the world’s first next-generation...
Source: https://incomestatements.info
Category: Stock Reports